← Browse by Condition
Medical Condition

hematopoietic and lymphoid system neoplasm

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for hematopoietic and lymphoid system neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematopoietic and lymphoid system neoplasm Clinical Trials

How many clinical trials are currently recruiting for hematopoietic and lymphoid system neoplasm?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for hematopoietic and lymphoid system neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematopoietic and lymphoid system neoplasm?
hematopoietic and lymphoid system neoplasm research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematopoietic and lymphoid system neoplasm clinical trial?
Eligibility criteria for hematopoietic and lymphoid system neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
City of Hope Medical Center 2 trials
Mayo Clinic 2 trials

Recruiting Clinical Trials

NCT05772130
Recruiting
Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study
Enrollment
240 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT06015932
Recruiting
Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
Enrollment
400 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06151730
Recruiting
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Enrollment
100 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06059391 Phase 2
Recruiting
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment
216 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →

Related Conditions

malignant solid neoplasm (2) chronic lymphocytic leukemia (2) hereditary malignant neoplasm (1) metastatic malignant solid neoplasm (1) mantle cell lymphoma (1) marginal zone lymphoma (1) waldenstrom macroglobulinemia (1) acute lymphoblastic leukemia (1) acute myeloid leukemia (1) chronic myeloid leukemia bcr abl1 positive (1) hodgkin lymphoma (1) myelodysplastic syndrome (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology